Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Gram-Positive Bacterial Infections; Escherichia Coli Infections; Klebsiella Infections
Intervention: piperacillin-tazobactam (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Summary
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and
restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing
Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Clinical Details
Official title: Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.
Study design: Observational Model: Case Control, Time Perspective: Longitudinal
Eligibility
Minimum age: 15 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Eligible patients of either sex, 15 years of age or older
- Patients who are admitted to the department of hematology and oncology
- Provide written informed consent
Exclusion Criteria:
- Patients who have hypersensitivity to β-lactam antibiotics
- Female who are pregnant or breast-feeding
- Any underlying conditions or non-infectious diseases that will be ultimately fatal
within 30 days
Locations and Contacts
Seoul 133-792, Korea, Republic of
Additional Information
Starting date: February 2005
Last updated: March 14, 2007
|
